{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:16:50Z","timestamp":1781619410115,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory joint diseases in children. The presence and role of antibodies targeting citrullinated proteins remains unclear in this patient group. This study aimed to assess antibodies against citrullinated peptides in a Swedish cohort of patients with juvenile idiopathic arthritis and to explore their associations with clinical features and genetic markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma samples from 334 patients with juvenile idiopathic arthritis were analyzed for antibodies against cyclic citrullinated peptides using enzyme-linked immunosorbent assay. A subset of 100 patients underwent detailed profiling of antibody reactivity to 15 citrullinated peptides and their non-citrullinated counterparts using a multiplex microarray. Rheumatoid factor, antinuclear antibodies, and HLA-DRB1 genotypes were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antibodies against cyclic citrullinated peptides were detected in 6.2% of patients, with the highest prevalence in the rheumatoid factor\u2013positive polyarthritis subtype. These patients were older at disease onset and more frequently carried HLA-DRB1 shared epitope alleles. Among the 100 profiled patients, 85% of those positive for cyclic citrullinated peptide antibodies showed reactivity to at least one citrullinated peptide, compared to 19% of antibody-negative patients. The most frequent reactivities were directed against peptides derived from filaggrin, fibrinogen, vimentin, and enolase. Reactivity to non-citrullinated peptides was minimal. A significant association was found between reactivity to citrullinated vimentin and the presence of HLA-DRB1 shared epitope alleles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals a distinct pattern of antibody reactivity to citrullinated peptides in a subset of patients with juvenile idiopathic arthritis, suggesting a biologically distinct subgroup with similarities to adult rheumatoid arthritis. These findings identify ACPA-positive JIA as a unique subgroup of young patients and underscore an opportunity to investigate early molecular events driving the immune response to citrullinated proteins and the pathogenesis of arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-025-01177-1","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T09:54:09Z","timestamp":1763805249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Presence and reactivities of antibodies directed to citrullinated peptides in a Swedish JIA cohort"],"prefix":"10.1186","volume":"23","author":[{"given":"Raya","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mathsson-Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Skriner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Serre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Padyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Erlandsson","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"2","key":"1177_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"4","key":"1177_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.autrev.2005.09.011","volume":"5","author":"AT Borchers","year":"2006","unstructured":"Borchers AT, et al. Juvenile idiopathic arthritis. Autoimmun Rev. 2006;5(4):279\u201398.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1177_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/art.20773","volume":"52","author":"ED Ferucci","year":"2005","unstructured":"Ferucci ED, et al. Antibodies against Cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52(1):239\u201346.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1177_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","volume":"6","author":"WJ van Venrooij","year":"2006","unstructured":"van Venrooij WJ, Zendman AJ, Pruijn GJ. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006;6(1):37\u201341.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1177_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","volume":"152","author":"P Whiting","year":"2010","unstructured":"Whiting P PF, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(7):456\u201364. W155-66.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1177_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: smoking May trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38\u201346.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1177_CR7","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, et al. Antibodies against Cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741\u20139.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1177_CR8","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1136\/annrheumdis-2015-207871","volume":"75","author":"JL Nam","year":"2016","unstructured":"Nam JL, et al. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new nonspecific musculoskeletal symptoms - a cohort study. Ann Rheum Dis. 2016;75(8):1452\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1177_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73(5):854\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1177_CR10","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.34344","volume":"64","author":"MK Demoruelle","year":"2012","unstructured":"Demoruelle MK, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756\u201361.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1177_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.berh.2017.09.015","volume":"31","author":"G Schett","year":"2017","unstructured":"Schett G. The role of ACPAs in at-risk individuals: early targeting of the bone and joints. Best Pract Res Clin Rheumatol. 2017;31(1):53\u20138.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"1177_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13075-020-02366-x","volume":"22","author":"K Murata","year":"2020","unstructured":"Murata K, et al. Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort. Arthritis Res Ther. 2020;22(1):268.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1177_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","volume":"36","author":"E Martin-Mola","year":"2016","unstructured":"Martin-Mola E, et al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36(8):1043\u201363.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1177_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.110879","volume":"39","author":"J Lipinska","year":"2012","unstructured":"Lipinska J, et al. Anticitrullinated protein antibodies and radiological progression in juvenile idiopathic arthritis. J Rheumatol. 2012;39(5):1078\u201387.","journal-title":"J Rheumatol"},{"issue":"5","key":"1177_CR15","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AH van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil AH, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7(5):R949\u201358.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1177_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/art.33376","volume":"64","author":"S Prahalad","year":"2012","unstructured":"Prahalad S, et al. Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum. 2012;64(3):925\u201330.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1177_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard.2010.131102","volume":"70","author":"A Ioan-Facsinay","year":"2011","unstructured":"Ioan-Facsinay A, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and nonoverlapping reactivities. Ann Rheum Dis. 2011;70(1):188\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1177_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.0105-2896.2009.00850.x","volume":"233","author":"N Wegner","year":"2010","unstructured":"Wegner N, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233(1):34\u201354.","journal-title":"Immunol Rev"},{"issue":"5","key":"1177_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/annrheumdis-2012-201484","volume":"72","author":"K Lundberg","year":"2013","unstructured":"Lundberg K, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein\/peptide antibody fine specificity profile. Ann Rheum Dis. 2013;72(5):652\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1177_CR20","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1136\/ard.2009.124537","volume":"69","author":"D van der Woude","year":"2010","unstructured":"van der Woude D, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010;69(8):1554\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1177_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ajhg.2019.08.002","volume":"105","author":"C Terao","year":"2019","unstructured":"Terao C, et al. Distinct HLA associations with rheumatoid arthritis subsets defined by serological subphenotype. Am J Hum Genet. 2019;105(3):616\u201324.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1177_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1546-0096-10-29","volume":"10","author":"AE Tebo","year":"2012","unstructured":"Tebo AE, et al. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2012;10(1):29.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"1177_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/ard.61.7.608","volume":"61","author":"T Avcin","year":"2002","unstructured":"Avcin T, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2002;61(7):608\u201311.","journal-title":"Ann Rheum Dis"},{"key":"1177_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1546-0096-9-8","volume":"9","author":"BE Gilliam","year":"2011","unstructured":"Gilliam BE, et al. Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2011;9:8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1177_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1546-0096-11-31","volume":"11","author":"BE Gilliam","year":"2013","unstructured":"Gilliam BE, Chauhan AK, Moore TL. Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2013;11(1):31.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1177_CR26","doi-asserted-by":"crossref","unstructured":"Pang SY et al. Diagnostic performance of anti-citrullinated protein\/peptide antibodies in juvenile idiopathic arthritis. Genet Mol Res. 2016;15(2).","DOI":"10.4238\/gmr.15028641"},{"issue":"5","key":"1177_CR27","doi-asserted-by":"publisher","first-page":"R201","DOI":"10.1186\/ar4039","volume":"14","author":"M Hansson","year":"2012","unstructured":"Hansson M, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14(5):R201.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1177_CR28","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/eji.200535790","volume":"36","author":"M Sebbag","year":"2006","unstructured":"Sebbag M, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol. 2006;36(8):2250\u201363.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1177_CR29","doi-asserted-by":"publisher","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","volume":"8","author":"X Jia","year":"2013","unstructured":"Jia X, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE. 2013;8(6):e64683.","journal-title":"PLoS ONE"},{"issue":"9","key":"1177_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, et al. 2010 rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1177_CR31","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2018-214967","volume":"78","author":"M Sun","year":"2019","unstructured":"Sun M, et al. Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. Ann Rheum Dis. 2019;78(12):1621\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1177_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a Cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155\u201363.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1177_CR33","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/annrheumdis-2015-208094","volume":"75","author":"G Wigerblad","year":"2016","unstructured":"Wigerblad G, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis. 2016;75(4):730\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1177_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75(4):721\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1177_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13063-019-3403-7","volume":"20","author":"M Al-Laith","year":"2019","unstructured":"Al-Laith M, et al. Arthritis prevention in the preclinical phase of RA with abatacept (the APIPPRA study): a multicentre, randomized, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019;20(1):429.","journal-title":"Trials"},{"issue":"6","key":"1177_CR36","doi-asserted-by":"publisher","first-page":"105617","DOI":"10.1016\/j.jbspin.2023.105617","volume":"90","author":"B Raposo","year":"2023","unstructured":"Raposo B, Gronwall C. The diversity of anti-citrulline reactivity and ACPA-associated phenotypes. Joint Bone Spine. 2023;90(6):105617.","journal-title":"Joint Bone Spine"},{"key":"1177_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2014.07.032","volume":"437","author":"T Webb","year":"2014","unstructured":"Webb T, et al. Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. Clin Chim Acta. 2014;437:161\u20137.","journal-title":"Clin Chim Acta"},{"issue":"9","key":"1177_CR38","first-page":"1829","volume":"31","author":"JM Low","year":"2004","unstructured":"Low JM, et al. Determination of anti-cyclic citrullinated peptide antibodies in the Sera of patients with juvenile idiopathic arthritis. J Rheumatol. 2004;31(9):1829\u201333.","journal-title":"J Rheumatol"},{"issue":"12","key":"1177_CR39","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1515\/CCLM.2009.288","volume":"47","author":"AT Kuna","year":"2009","unstructured":"Kuna AT, et al. Antibodies to mutated citrullinated vimentin and antibodies to Cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med. 2009;47(12):1525\u201330.","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"1177_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/ard.2007.084855","volume":"67","author":"RH Syed","year":"2008","unstructured":"Syed RH, Gilliam BE, Moore TL. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67(7):1049\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1177_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10067-015-2971-5","volume":"35","author":"M Sparchez","year":"2016","unstructured":"Sparchez M, et al. Evaluation of anti-cyclic citrullinated peptide antibodies May be beneficial in RF-negative juvenile idiopathic arthritis patients. Clin Rheumatol. 2016;35(3):601\u20137.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1177_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajhg.2010.12.007","volume":"88","author":"F Kurreeman","year":"2011","unstructured":"Kurreeman F, et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multiethnic cohort derived from electronic health records. Am J Hum Genet. 2011;88(1):57\u201369.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1177_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/rheumatology\/kei133","volume":"45","author":"P Dewint","year":"2006","unstructured":"Dewint P, et al. Effect of age on prevalence of anticitrullinated protein\/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2006;45(2):204\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1177_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13075-020-02191-2","volume":"22","author":"E Reed","year":"2020","unstructured":"Reed E, et al. Presence of autoantibodies in seronegative rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther. 2020;22(1):170.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1177_CR45","first-page":"800","volume":"28","author":"H Morbach","year":"2010","unstructured":"Morbach H, et al. Prevalence of antibodies against mutated citrullinated vimentin and Cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2010;28(5):800.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1177_CR46","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/annrheumdis-2012-202868","volume":"73","author":"M Cornillet","year":"2014","unstructured":"Cornillet M, et al. The fibrin-derived citrullinated peptide beta60-74Cit(6)(0),(7)(2),(7)(4) bears the major ACPA epitope recognized by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies. Ann Rheum Dis. 2014;73(6):1246\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1177_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2017-211782","volume":"77","author":"J Ronnelid","year":"2018","unstructured":"Ronnelid J, et al. Anticitrullinated protein\/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis. 2018;77(2):203\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1177_CR48","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/art.40587","volume":"70","author":"SE Elliott","year":"2018","unstructured":"Elliott SE, et al. Affinity maturation drives epitope spreading and generation of Proinflammatory Anti-Citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(12):1946\u201358.","journal-title":"Arthritis Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01177-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01177-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:22:46Z","timestamp":1781616166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-025-01177-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01177-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was given by all study participants and\/or their legal guardians. Ethical approval for JIA patients and healthy references was obtained from the Regional Review Board in Stockholm (2009\/1139-31, 2010\/165\u2009\u2212\u200932, 02-509 Dnr 03\u2013067).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was given by research participants or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}